Media Kit

Featured News

Bayer and BlueRock Therapeutics logos side by side on a light blue background

Announcement

Parkinson's Disease

BlueRock Therapeutics’ investigational cell therapy bemdaneprocel for Parkinson’s disease shows positive data at 24-months

Announcement

Ophthalmology

BlueRock Therapeutics announces FDA clearance of IND application for investigational iPSC-derived cell therapy OpCT-001 for the treatment of primary photoreceptor diseases

Bayer and BlueRock Therapeutics logos side by side on a light blue background

Announcement

Neurology

Parkinson's Disease

BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease cell therapy candidate bemdaneprocel

multicolor title graphic for cell & gene the podcast featuring BlueRock Therapeutics

Podcast

Cell & Gene The Podcast | Inside BlueRock Therapeutics' Parkinson's Disease Trial

See All

Media Library

Lab
Headshots
Logos
Offices

Alan Stevenson

General Counsel

Amit Rakhit

Chief Development and Medical Officer

Seth Ettenberg, Ph.D.

President and Chief Executive Officer

Natasha Rathee

SVP, Finance

Rebecca Milbury

SVP, People and Culture

Melissa Mudrick

SVP, Quality and Compliance

Craig Beasley

Chief Technology Officer

Stefan Irion, M.D.

Chief Scientific Officer

Cambridge

New York

Berlin

Toronto

Media Contact

Contact@BlueRockTX.com

Video

B-Roll

B-Roll: Lab 1

B-Roll: Lab 2

B-Roll: Lab 3

B-Roll: Lab 4

B-Roll: Lab 5

B-Roll: Lab 6

B-Roll: PSC-Derived Cardiomyocytes

Explore more with BlueRock

Cell Therapy

Our Programs

Our Pipeline

Careers

Keep up to date with the latest BlueRock Therapeutics news and updates

Follow BlueRock Therapeutics on Linkedin